Updates on HER2-Directed ADCs Across Solid Tumors - Episode 4

Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

, , , ,

Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.

EP. 1: Assessing HER2 Status Across Tumor Types
EP. 2: ADCs Targeting HER2+ Breast Cancer
EP. 3: ADCs Targeting HER2+ Gynecologic Cancers
Now Viewing
EP. 4: Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06
EP. 5: ADCs Targeting GI Cancers
EP. 6: ADCs Targeting HER2+ Lung Cancer
EP. 7: Impact of ADCs on Brain Metastases
EP. 8: ADCs Targeting HER2+ GU Cancers
EP. 9: Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types
EP. 10: The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines
EP. 11: Managing ILD and Pneumonitis Risk From ADCs
EP. 12: Managing Toxicities in Short- and Long-Term Treatment with ADCs
EP. 13: Managing Hematologic AEs Associated with ADC Treatments
EP. 14: Management of Emetogenicity of Antibody-Drug Conjugates
EP. 15: ADC Sequencing
EP. 16: Emerging ADCs in Development
EP. 17: Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy
EP. 18: The Future for HER2-Directed ADCs
EP. 19: Key Takeaways and Closing Thoughts on ADCs

Video content above is prompted by the following:

  • Can you please offer an overview of the primary results from the DESTINY-PanTumor02 trial (Meric-Bernstam_J Clin Oncol_2024), specifically in regard to each of the following:
    • cervical
    • ovarian cancers
    • endometrial
      • STATICE trial results (Nishikawa J Clin Oncol 2023)
      • What is the potential for DB-1303 in endometrial cancer (Moore_J Clin Oncol_2023)
  • Where in the treatment sequencing do you expect HER2-direct ADCs to fit?